Transgene Reports PoxSTG-EEV Reduced Tumor Growth in Preclinical Study
Transgene reported that its PoxSTG-EEV candidate reduced tumor growth in a preclinical study and said it will present results.
Story updates
04:47:00 PM UTC
SquawkNews
Transgene said preclinical studies found PoxSTG-EEV enhanced cytotoxic activity and intratumoral dissemination versus conventional oncolytic vaccinia viruses. In mouse models, IV administration significantly reduced tumor growth and prolonged survival; no numerical results were provided.Material De…